WallStSmart

Amgen Inc (AMGN)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amgen Inc generates 5% more annual revenue ($37.22B vs $35.48B). AMGN leads profitability with a 21.0% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.36. AMGN earns a higher WallStSmart Score of 62/100 (C+).

AMGN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 5.0
Piotroski: 4/9

MDT

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNFair Value (-2.2%)

Margin of Safety

-2.2%

Fair Value

$321.89

Current Price

$331.70

$9.81 premium

UndervaluedFair: $321.89Overvalued
MDTUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$107.79

Current Price

$76.15

$31.64 discount

UndervaluedFair: $107.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.2/10
Return on EquityProfitability
101.3%10/10

Every $100 of equity generates 101 in profit

Operating MarginProfitability
33.8%10/10

Strong operational efficiency at 33.8%

Market CapQuality
$177.71B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

Free Cash FlowQuality
$1.48B8/10

Generating 1.5B in free cash flow

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$100.09B9/10

Large-cap with strong market position

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

AMGN3 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Price/BookValuation
19.5x4/10

Trading at 19.5x book value

EPS GrowthGrowth
4.4%4/10

4.4% earnings growth

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.36 suggests the stock is reasonably priced for its growth.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

AMGN profiles as a mature stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.63 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

AMGN scores higher overall (62/100 vs 58/100), backed by strong 21.0% margins. MDT offers better value entry with a 27.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?